Dia.Com's Quality Systems are certified to the ISO/ TS 16949:2002 Quality Management System, an International standard developed to supersede the QS-9000 Quality System. ISO/ TS 16949:2002 uses a process approach when developing, implementing, and improving the effectiveness of a quality management system, to enhance customer satisfaction by meeting customer requirements.

Dia•Com is a leading international provider of innovative, cost-effective molded diaphragm solutions critical to the operation of essential systems and equipment in industrial, automotive, aerospace, medical instrumentation, and food and water processing applications. The company's reputation for excellence is based on superior quality in the design, manufacture and application of its high-performance, state-of-the-art, fabric-reinforced and homogeneous elastomeric diaphragm seals.

The company was founded in 1983 as a supplier of custom and standard diaphragm seals known for reliability and dependability. Today, Dia•Com, with worldwide corporate headquarters in Amherst, New Hampshire, focuses on forming strategic customer partnerships critical to the development of unique, technologically superior design solutions linked to its customers' success. As an extension of its customers’ design teams, Dia•Com offers a broad range of custom diaphragm solutions that are “designed for manufacturing,” and as a result, are more comprehensive, robust and cost-effective than competitive products.

Effects of perfluoro-n-octanoic acid, perfluoro-n-decanoic acid, and clofibrate on hepatic phosphorus metabolism in rats and guinea pigs in vivo.

Reo NV, Goecke CM, Narayanan L, Jarnot BM.

Source

Department of Biochemistry and Molecular Biology/Kettering-Scott Magnetic Resonance Laboratory, Wright State University, Dayton, Ohio.

Abstract

Phosphorus-31 nuclear magnetic resonance (NMR) spectroscopy was used to study the effects of perfluoro-n-octanoic acid (PFOA), perfluoro-n-decanoic acid (PFDA), and clofibrate (CLOF) on liver phosphorus metabolism in rats and guinea pigs in vivo. All three compounds are known to cause peroxisome proliferation in rats but not in guinea pigs. The data indicate that indices related to overall tissue viability (i.e., adenosine triphosphate levels) remain unaffected at the doses and experimental times investigated for all treatments and both species. PFDA-treated rats revealed a marked increase in a liver phosphomonoester resonance compared with corresponding controls (p < or = 0.01); no such effect was observed in guinea pigs. This particular 31P NMR signal was identified as phosphocholine (PCho) and was found to steadily increase in concentration at consecutive days post-PFDA treatment, reaching 6.26 +/- 0.29 mumol/g liver at 5 days. This is fourfold greater than the PCho levels determined in livers from corresponding pair-fed control rats. The elevation in liver PCho is a specific response of PFDA treatment in rats and is not simply related to peroxisome proliferation in general, since neither PFOA nor CLOF produce such an effect. The data suggest a unique effect of PFDA on liver phospholipid metabolism, specifically phosphatidylcholine, which may involve enhanced phospholipid turnover via phosphatidylcholine-specific phospholipase C activity.